Literature DB >> 31092404

Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer.

Samuel L Washington1, John Neuhaus2, Maxwell V Meng3, Sima P Porten1.   

Abstract

BACKGROUND: Racial disparities in guideline-based, appropriate treatment (ApT) may be a significant driving force for differences in survival for people with nonmetastatic muscle-invasive bladder cancer (MIBC). We hypothesize that receipt of ApT is influenced by factors such as race and socioeconomic status, irrespective of neighborhood-level differences in healthcare, variations in practice patterns, and clinical characteristics of patients with nonmetastatic MIBC.
METHODS: Within the National Cancer Database, we identified individuals diagnosed with MIBC between 2004 and 2013. Multivariable logistic regression and mixed effects modelling was used to examine predictors of ApT, clustered within institutions.
RESULTS: A total of 51,350 individuals had clinically staged nonmetastatic, lymph node-negative MIBC. Black individuals comprised 6.4% of the cohort. Mean age was 72.6 years (SD 11.6) with a male predominance (71.4%). Less than half received ApT (42.6%). Fewer black individuals received ApT compared with white individuals (37% vs. 43%, P < 0.001). When clustered by institution, the odds of ApT were 21% lower for black individuals [odds ratio (OR), 0.79; 95% confidence interval (CI), 0.73-0.87] compared with white individuals with nonmetastatic MIBC. When restricted to higher volume centers with more diverse populations, black individuals had 25% lower odds of ApT (OR, 0.75; 95% CI, 0.61-0.91; P < 0.01), compared with white counterparts.
CONCLUSIONS: Racial disparities in treatment persisted after accounting for various clinical factors and social determinants of health. Future efforts should focus on addressing racial bias to improve disparities in bladder cancer treatment. IMPACT: If we are not delivering evidence-based care due to these biases (after accounting for access and biology), then it is expected that patients will experience inferior outcomes. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 31092404      PMCID: PMC6679737          DOI: 10.1158/1055-9965.EPI-18-1280

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  20 in total

1.  Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007.

Authors:  Ugo Fedeli; Stacey A Fedewa; Elizabeth M Ward
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

2.  How do differences in treatment impact racial and ethnic disparities in acute myeloid leukemia?

Authors:  Manali I Patel; Yifei Ma; Beverly Mitchell; Kim F Rhoads
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-02       Impact factor: 4.254

3.  Factors affecting outcomes after radical cystectomy in African Americans.

Authors:  Badrinath R Konety; Veerasathpurush Allareddy; Peter R Carroll
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

4.  An ecological approach to understanding black-white disparities in perinatal mortality.

Authors:  Amina P Alio; Alice R Richman; Heather B Clayton; Delores F Jeffers; Deanna J Wathington; Hamisu M Salihu
Journal:  Matern Child Health J       Date:  2009-06-27

5.  Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type.

Authors:  Anthony T Corcoran; Elizabeth Handorf; Daniel Canter; Jeffrey J Tomaszewski; Justin E Bekelman; Simon P Kim; Robert G Uzzo; Alexander Kutikov; Marc C Smaldone
Journal:  BJU Int       Date:  2014-07-14       Impact factor: 5.588

6.  Racial variation in the quality of surgical care for bladder cancer.

Authors:  Daniel A Barocas; Joann Alvarez; Tatsuki Koyama; Christopher B Anderson; Darryl T Gray; Jay H Fowke; Chaochen You; Sam S Chang; Michael S Cookson; Joseph A Smith; David F Penson
Journal:  Cancer       Date:  2013-12-11       Impact factor: 6.860

7.  The effect of race and sex on physicians' recommendations for cardiac catheterization.

Authors:  K A Schulman; J A Berlin; W Harless; J F Kerner; S Sistrunk; B J Gersh; R Dubé; C K Taleghani; J E Burke; S Williams; J M Eisenberg; J J Escarce
Journal:  N Engl J Med       Date:  1999-02-25       Impact factor: 91.245

8.  Survival experience of black patients and white patients with bladder carcinoma.

Authors:  George R Prout; Margaret N Wesley; Peter G McCarron; Vivien W Chen; Raymond S Greenberg; Robert M Mayberry; Brenda K Edwards
Journal:  Cancer       Date:  2004-02-01       Impact factor: 6.860

9.  Geographic analysis of urologist density and prostate cancer mortality in the United States.

Authors:  Nengliang Yao; Steven M Foltz; Anobel Y Odisho; David C Wheeler
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more
  6 in total

1.  Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer.

Authors:  Nikhil V Kotha; Abhishek Kumar; Edmund M Qiao; Alex S Qian; Rohith S Voora; Vinit Nalawade; A Karim Kader; Rana R McKay; Tyler F Stewart; Brent S Rose
Journal:  J Natl Cancer Inst       Date:  2022-04-11       Impact factor: 13.506

2.  Underutilization of Surgical Standard of Care for Insured Men with Invasive Penile Cancer.

Authors:  Edward K Chang; Rishi R Sekar; Sarah K Holt; John L Gore; Jonathan L Wright; Yaw A Nyame
Journal:  Urol Pract       Date:  2021-05-01

3.  Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer.

Authors:  Nikhil V Kotha; Abhishek Kumar; Tyler J Nelson; Edmund M Qiao; Alex S Qian; Rohith S Voora; Rana R McKay; Brent S Rose; Tyler F Stewart
Journal:  Urol Oncol       Date:  2022-02-23       Impact factor: 2.954

4.  Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation.

Authors:  Nikhil V Kotha; Abhishek Kumar; Tyler J Nelson; Edmund M Qiao; Alex S Qian; Rohith S Voora; Rana R McKay; Tyler F Stewart; Brent S Rose
Journal:  Adv Radiat Oncol       Date:  2021-10-25

5.  Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer.

Authors:  Samuel L Washington; Steven E Gregorich; Maxwell V Meng; Anne M Suskind; Sima P Porten
Journal:  Cancer Med       Date:  2020-09-01       Impact factor: 4.452

6.  A mediation analysis to explain socio-economic differences in bladder cancer survival.

Authors:  Beth Russell; Mieke V Hemelrijck; Truls Gårdmark; Lars Holmberg; Pardeep Kumar; Andrea Bellavia; Christel Häggström
Journal:  Cancer Med       Date:  2020-08-26       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.